EP1851300A2 - General solvent synthesis, production and utility - Google Patents
General solvent synthesis, production and utilityInfo
- Publication number
- EP1851300A2 EP1851300A2 EP06704104A EP06704104A EP1851300A2 EP 1851300 A2 EP1851300 A2 EP 1851300A2 EP 06704104 A EP06704104 A EP 06704104A EP 06704104 A EP06704104 A EP 06704104A EP 1851300 A2 EP1851300 A2 EP 1851300A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- added
- combination
- entries
- effective
- medical conditions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002904 solvent Substances 0.000 title claims description 15
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 230000015572 biosynthetic process Effects 0.000 title description 3
- 238000003786 synthesis reaction Methods 0.000 title description 2
- 150000003839 salts Chemical class 0.000 claims description 21
- 241001465754 Metazoa Species 0.000 claims description 19
- 229910052783 alkali metal Inorganic materials 0.000 claims description 15
- 150000001340 alkali metals Chemical class 0.000 claims description 15
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 11
- 229910001424 calcium ion Inorganic materials 0.000 claims description 11
- 210000001519 tissue Anatomy 0.000 claims description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 7
- 206010029148 Nephrolithiasis Diseases 0.000 claims description 6
- 150000003863 ammonium salts Chemical class 0.000 claims description 6
- 229910001422 barium ion Inorganic materials 0.000 claims description 6
- XDFCIPNJCBUZJN-UHFFFAOYSA-N barium(2+) Chemical compound [Ba+2] XDFCIPNJCBUZJN-UHFFFAOYSA-N 0.000 claims description 6
- 230000002308 calcification Effects 0.000 claims description 6
- 201000001883 cholelithiasis Diseases 0.000 claims description 6
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Chemical class [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 claims description 6
- 229910001427 strontium ion Inorganic materials 0.000 claims description 6
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 claims description 6
- 208000000913 Kidney Calculi Diseases 0.000 claims description 5
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 208000001130 gallstones Diseases 0.000 claims description 5
- 230000002440 hepatic effect Effects 0.000 claims description 5
- 239000010802 sludge Substances 0.000 claims description 5
- 206010010904 Convulsion Diseases 0.000 claims description 4
- 206010003119 arrhythmia Diseases 0.000 claims description 4
- 230000036461 convulsion Effects 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical class CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims description 3
- 208000020084 Bone disease Diseases 0.000 claims description 3
- XTEGARKTQYYJKE-UHFFFAOYSA-M Chlorate Chemical class [O-]Cl(=O)=O XTEGARKTQYYJKE-UHFFFAOYSA-M 0.000 claims description 3
- 208000001132 Osteoporosis Diseases 0.000 claims description 3
- 150000003842 bromide salts Chemical class 0.000 claims description 3
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 229940005989 chlorate ion Drugs 0.000 claims description 3
- 150000001805 chlorine compounds Chemical class 0.000 claims description 3
- 229910001914 chlorine tetroxide Inorganic materials 0.000 claims description 3
- TVWHTOUAJSGEKT-UHFFFAOYSA-N chlorine trioxide Chemical compound [O]Cl(=O)=O TVWHTOUAJSGEKT-UHFFFAOYSA-N 0.000 claims description 3
- 210000004087 cornea Anatomy 0.000 claims description 3
- 230000007547 defect Effects 0.000 claims description 3
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 claims description 3
- 150000004694 iodide salts Chemical class 0.000 claims description 3
- 210000000653 nervous system Anatomy 0.000 claims description 3
- 235000021317 phosphate Nutrition 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 3
- 210000004127 vitreous body Anatomy 0.000 claims description 3
- 208000006386 Bone Resorption Diseases 0.000 claims description 2
- 208000003870 Drug Overdose Diseases 0.000 claims description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
- 206010033296 Overdoses Diseases 0.000 claims description 2
- 231100000643 Substance intoxication Toxicity 0.000 claims description 2
- 206010070863 Toxicity to various agents Diseases 0.000 claims description 2
- 230000024279 bone resorption Effects 0.000 claims description 2
- 231100000725 drug overdose Toxicity 0.000 claims description 2
- 235000012907 honey Nutrition 0.000 claims description 2
- 230000035987 intoxication Effects 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- 239000011572 manganese Substances 0.000 claims description 2
- 239000003599 detergent Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910001414 potassium ion Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- KWKXNDCHNDYVRT-UHFFFAOYSA-N dodecylbenzene Chemical class CCCCCCCCCCCCC1=CC=CC=C1 KWKXNDCHNDYVRT-UHFFFAOYSA-N 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000003499 exocrine gland Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003348 petrochemical agent Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/66—Non-ionic compounds
- C11D1/835—Mixtures of non-ionic with cationic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
- A61K35/64—Insects, e.g. bees, wasps or fleas
- A61K35/644—Beeswax; Propolis; Royal jelly; Honey
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D1/00—Detergent compositions based essentially on surface-active compounds; Use of these compounds as a detergent
- C11D1/86—Mixtures of anionic, cationic, and non-ionic compounds
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D3/00—Other compounding ingredients of detergent compositions covered in group C11D1/00
- C11D3/02—Inorganic compounds ; Elemental compounds
- C11D3/04—Water-soluble compounds
- C11D3/046—Salts
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/02—Inorganic compounds
- C11D7/04—Water-soluble compounds
- C11D7/10—Salts
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11D—DETERGENT COMPOSITIONS; USE OF SINGLE SUBSTANCES AS DETERGENTS; SOAP OR SOAP-MAKING; RESIN SOAPS; RECOVERY OF GLYCEROL
- C11D7/00—Compositions of detergents based essentially on non-surface-active compounds
- C11D7/22—Organic compounds
- C11D7/26—Organic compounds containing oxygen
- C11D7/268—Carbohydrates or derivatives thereof
Definitions
- Detergents are formed of surface compounds which are not environmentally safe. They are either natural or synthetic. Oil soluble detergents are used in gasoline and lubricating oils to hold particulate impurities in suspension. Among the water soluble detergents, alcohols and common soaps are effective. Still more so are the synthetic types (syndets) such as sulphonated dodecylbenzene and similar alkylates. The linear alkyl sulphonates (LAS) are more biodegradable than are the branched-chain type; they are made from petrochemicals by various cracking and polymerization techniques. Three general types of detergents are in use; anionic, cationic, and non-ionic.
- shock wave lithotripsy is used, or surgically, or medicines to change ph of urine to prevent further stone formation.
- Calcium is essential for human and animal cells where it is essential as an integral part of bone mineral, an integral part of the cell wall and its biological function, the essential link between excitation and contraction in all forms of muscle, the essential link between excitation and secretion in both endocrine and exocrine glands and an activator, regulator or inhibitor of key enzymes.
- Glucose is essential for absorption of other solutes.
- the preparation of any of the mixtures described in this patent includes glucose or a carbohydrate in different proportions.
- Solubility rules include; -All salts of the alkali metals are soluble, - All salts of the ammonium ion NH 4 + are soluble, - All salts of nitrate ion (NO 3 " ) are soluble, - All salts of chlorate ion (ClO 3 " ) are soluble, - All salts of perchlorate ion (ClO 4 " ) are soluble, - All salts of acetate ion (C 2 H 3 O 2 " ) are soluble, - All chlorides, bromides, and iodides (except Ag + , Pb + , and Hg 2 2+ ) are soluble, - All sulphates (SO 4 2" ) (except those of Ca 2+ , Sr 2+ , Ba 2+ and Pb + ) are soluble, - All metal oxides .are insoluble, except those of alkali metals, Ca 2+ , Sr 2+ , Ba
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Insects & Arthropods (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Animal Husbandry (AREA)
- Neurology (AREA)
Description
General solvent synthesis, production and utility
Technical Field:
1. Medicine
2. Chemistry
Background Art:
Detergents are formed of surface compounds which are not environmentally safe. They are either natural or synthetic. Oil soluble detergents are used in gasoline and lubricating oils to hold particulate impurities in suspension. Among the water soluble detergents, alcohols and common soaps are effective. Still more so are the synthetic types (syndets) such as sulphonated dodecylbenzene and similar alkylates. The linear alkyl sulphonates (LAS) are more biodegradable than are the branched-chain type; they are made from petrochemicals by various cracking and polymerization techniques. Three general types of detergents are in use; anionic, cationic, and non-ionic.
To overcome tissue metastatic calcification or stones developing in various duct systems of human body as renal stones or gall bladder stones shock wave lithotripsy is used, or surgically, or medicines to change ph of urine to prevent further stone formation.
Calcium is essential for human and animal cells where it is essential as an integral part of bone mineral, an integral part of the cell wall and its biological function, the essential link between excitation and contraction in all forms of muscle, the essential link between excitation and secretion in both endocrine and exocrine glands and an activator, regulator or inhibitor of key enzymes.
Glucose is essential for absorption of other solutes. Depending on this solute drag the preparation of any of the mixtures described in this patent includes glucose or a carbohydrate in different proportions.
Disclosure of Invention:
Solubility rules include; -All salts of the alkali metals are soluble, - All salts of the ammonium ion NH4 + are soluble, - All salts of nitrate ion
(NO3 ") are soluble, - All salts of chlorate ion (ClO3 ") are soluble, - All salts of perchlorate ion (ClO4 ") are soluble, - All salts of acetate ion (C2H3O2 ") are soluble, - All chlorides, bromides, and iodides (except Ag+, Pb+, and Hg2 2+) are soluble, - All sulphates (SO4 2") (except those of Ca2+, Sr2+, Ba2+ and Pb+) are soluble, - All metal oxides .are insoluble, except those of alkali metals, Ca2+, Sr2+, Ba2+ , - All carbonates (CO3 2") are insoluble, except those of alkali metals, and ammonium salts, - All phosphates (PO4 3") are insoluble, except those of alkali metals, and ammonium (NH4 +) salts, - All sulfides (S2 " ) are insoluble, except those of alkali metals, and ammonium salts.
The Novel Idea:
Using a mixture of different or any combinations of aqueous or anhydrous or molar volumes of these soluble salts is capable of :
1. Stain removal.
2. Functioning as a general solvent for any purpose.
3. Functioning as a general solvent for human or animal tissue calcification.
4. Functioning as a general solvent for human or animal tissue calculi in any system as renal calculi, gall stones, gall sludge etc.,
5. Delivering soluble calcium ions in medical conditions of convulsions and epilepsy of any aetiology.
6. Delivering soluble sodium and potassium ions in medical conditions of convulsions and epilepsy of any aetiology.
7. Delivering soluble calcium ions in medical conditions of osteoporosis of any aetiology.
8. Delivering soluble calcium ions in medical conditions of bone resorption of any aetiology.
9. Delivering soluble calcium ions in medical conditions of bone disease of any aetiology.
10. Delivering soluble calcium ions in medical conditions of cardiac arrhythmias of any aetiology.
11.Delivering soluble sodium and potassium ions in medical conditions of cardiac arrhythmias of any aetiology.
12. Delivering soluble ions in medical conditions of loss of transparency of eye lens, cornea, aqueous or vitreous body or loss of transparency of any component of eye of any aetiology.
13. Delivering soluble ions in medical conditions associated with development of atheromatous plaques in any site of human or animal body of any aetiology.
14. Delivering soluble ions in medical conditions associated with development of nervous system plaques in any site of human or animal body of any aetiology.
15. Delivering soluble ions in medical conditions associated with impulse conduction defects in any site of human or animal body of any aetiology.
16. Providing oxidation of aldoses to uronic acid and subsequent glucoronization of all substances in need for hepatic glucouronization.
Detailed Description of the Requested Patent:
Manufacturing, producing, preparing and processing a mixture of different combinations of anhydrous or aqueous or molar volumes of the following soluble salts : a- All salts of the alkali metals, b- All salts of the ammonium ion NH4 +, c- All salts of nitrate ion (NO3 "), d- All salts of chlorate ion (ClO3 '), e- All salts of perchlorate ion (ClO4 "), f- All salts of acetate ion (C2H3O2 "), g- All chlorides, bromides, and iodides (except Ag+, Pb+, and Hg2 2+), h- All sulphates (SO4 2") (except those of Ca2+, Sr2+, Ba2+ and Pb+), i- Oxides of alkali metals, Ca2+, Sr2+, Ba2+ , and Manganese j- Carbonates (CO3 2") of alkali metals, and ammonium salts, k- Phosphates (PO4 3") of alkali metals, and ammonium (NH4 +) salts,
1- Sulfides (S2 ") of alkali metals, and ammonium salts. m- Any single or all and any combination of carbohydrates. n- Any and all types of natural Honey.
Where:
i. All of "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general stain remover, ii. All of "a", "b", "c", "d"5 "e", "f", "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d"5 "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for any purpose. iii. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for prevention of human or animal tissue calcification. iv. All of "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for prevention of human or animal tissue calculi in any system as renal calculi, gall stones, gall sludge etc., v. All of "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for human or animal tissue calcification. vi. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for human or animal tissue calculi in any system as renal calculi, gall stones, gall sludge etc., vii. All of "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of convulsions and epilepsy of any aetiology.
viii. All of "a", "b"3 "c", "d", "e", "F , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F, "g", "h"3 "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of osteoporosis of any aetiology. ix. All of "a", "b", "c", "d", "e", "F , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to V or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of bone resoiption of any aetiology. x. All of "a", "b", "c", "d", "e", "f" , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of bone disease of any aetiology. xi. All of "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k"5 and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of cardiac arrhythmias of any aetiology. xii. All of "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of loss of transparency of eye lens, cornea, aqueous or vitreous body or loss of transparency of any component of eye of any aetiology. xiii. All of "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with development of atheromatous plaques in any site of human or animal body of any aetiology.
xiv. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d"3 "e", "f ', "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with development of nervous system plaques in any site of human or animal body of any aetiology. xv. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added . to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with impulse conduction defects in any site of human or animal body of any aetiology. xvi. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d"5 "e", "f ', "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with need for glucoronization of any and all substances in need for hepatic glucouronization. xvii. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with need for glucoronization of any and all drug overdose or intoxication in need for hepatic glucouronization.
Claims
1. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general stain remover.
2. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for any purpose.
3. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any
combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for prevention of human or animal tissue calcification.
4. All of "a", "b", "c'\ "d", "e", "f , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for prevention of human or animal tissue calculi in any system as renal calculi, gall stones, gall sludge etc.,
5. All of "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for human or animal tissue calcification.
6. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", as a general solvent for human or animal tissue calculi in any system as renal calculi, gall stones, gall sludge etc.,
7. All of "a", "b", "c", "d", "e", "F5 "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of convulsions and epilepsy of any aetiology.
8. All of "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of osteoporosis of any aetiology.
9. All of "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", in medical conditions of bone resorption of any aetiology.
10.A11 of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d"5 "e", "F , "g", "h"5 "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of bone disease of any aetiology.
11. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c"3 "d", "e", "F , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of cardiac arrhythmias of any aetiology.
12. All of "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions of loss of transparency of eye lens, cornea, aqueous or vitreous body or loss of transparency of any component of eye of any aetiology.
13. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with development of atheromatous plaques in any site of human or animal body of any aetiology.
14. All of "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with development of nervous system plaques in any site of human or animal body of any aetiology.
15. All of "a", "b", "c", "d", "e", "f, "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "F, "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to
"m" or "n" or "m+n", in medical conditions associated with impulse conduction defects in any site of human or animal body of any aetiology.
16. All of "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f , "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with need for glucoronization of any and all substances in need for hepatic glucouronization.
17. All of "a", "b", "c", "d", "e", "f", "g", "h", "i", "j", "k", and "1" are effective if used as "a", "b", "c", "d", "e", "f ', "g", "h", "i", "j", "k", and "1" added to "m" or "n" or "m+n" or as any combination of any or all entries of "a" through "1" added to "m" or "n" or "m+n", in medical conditions associated with need for glucoronization of any and all drug overdose or intoxication in need for hepatic glucouronization.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EG2005010036 | 2005-01-24 | ||
| PCT/EG2006/000004 WO2006076927A2 (en) | 2005-01-24 | 2006-01-22 | General solvent synthesis, production and utility |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP1851300A2 true EP1851300A2 (en) | 2007-11-07 |
| EP1851300A4 EP1851300A4 (en) | 2010-04-14 |
Family
ID=36692595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP06704104A Withdrawn EP1851300A4 (en) | 2005-01-24 | 2006-01-22 | General solvent synthesis, production and utility |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1851300A4 (en) |
| JP (1) | JP2008528793A (en) |
| KR (1) | KR20070101355A (en) |
| CN (1) | CN101107350A (en) |
| AP (1) | AP2007004107A0 (en) |
| AU (1) | AU2006207750A1 (en) |
| BR (1) | BRPI0614031A2 (en) |
| CA (1) | CA2594768A1 (en) |
| EA (1) | EA200701435A1 (en) |
| IL (1) | IL184597A0 (en) |
| MA (1) | MA29249B1 (en) |
| MX (1) | MX2007008979A (en) |
| NO (1) | NO20074191L (en) |
| TN (1) | TNSN07271A1 (en) |
| WO (1) | WO2006076927A2 (en) |
| ZA (1) | ZA200706091B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030191034A1 (en) * | 1999-09-02 | 2003-10-09 | The Procter & Gamble Company | Method of deodorizing and/or cleaning carpet using a composition comprising odor control agent |
| US20040033914A1 (en) * | 2002-08-14 | 2004-02-19 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Biphasic composition induced by polydextrose |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4542279B2 (en) * | 2001-03-30 | 2010-09-08 | 株式会社ファンケル | Cleaning composition |
| JP2002322491A (en) * | 2001-04-23 | 2002-11-08 | Fancl Corp | Cleansing composition |
| JP4625595B2 (en) * | 2001-06-06 | 2011-02-02 | 塩水港精糖株式会社 | Skin cleanser |
-
2006
- 2006-01-22 EP EP06704104A patent/EP1851300A4/en not_active Withdrawn
- 2006-01-22 AU AU2006207750A patent/AU2006207750A1/en not_active Abandoned
- 2006-01-22 CN CNA2006800030369A patent/CN101107350A/en active Pending
- 2006-01-22 EA EA200701435A patent/EA200701435A1/en unknown
- 2006-01-22 AP AP2007004107A patent/AP2007004107A0/en unknown
- 2006-01-22 JP JP2007555455A patent/JP2008528793A/en active Pending
- 2006-01-22 KR KR1020077019496A patent/KR20070101355A/en not_active Application Discontinuation
- 2006-01-22 WO PCT/EG2006/000004 patent/WO2006076927A2/en active Application Filing
- 2006-01-22 CA CA002594768A patent/CA2594768A1/en not_active Abandoned
- 2006-01-22 MX MX2007008979A patent/MX2007008979A/en unknown
- 2006-01-22 BR BRPI0614031-9A patent/BRPI0614031A2/en not_active IP Right Cessation
-
2007
- 2007-07-12 IL IL184597A patent/IL184597A0/en unknown
- 2007-07-13 TN TNP2007000271A patent/TNSN07271A1/en unknown
- 2007-07-23 ZA ZA200706091A patent/ZA200706091B/en unknown
- 2007-08-13 MA MA30135A patent/MA29249B1/en unknown
- 2007-08-15 NO NO20074191A patent/NO20074191L/en not_active Application Discontinuation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030191034A1 (en) * | 1999-09-02 | 2003-10-09 | The Procter & Gamble Company | Method of deodorizing and/or cleaning carpet using a composition comprising odor control agent |
| US20040033914A1 (en) * | 2002-08-14 | 2004-02-19 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Biphasic composition induced by polydextrose |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1851300A4 (en) | 2010-04-14 |
| KR20070101355A (en) | 2007-10-16 |
| EA200701435A1 (en) | 2008-10-30 |
| JP2008528793A (en) | 2008-07-31 |
| MA29249B1 (en) | 2008-02-01 |
| CA2594768A1 (en) | 2006-07-27 |
| NO20074191L (en) | 2007-08-15 |
| MX2007008979A (en) | 2007-09-21 |
| AP2007004107A0 (en) | 2007-08-31 |
| IL184597A0 (en) | 2007-10-31 |
| BRPI0614031A2 (en) | 2011-03-01 |
| CN101107350A (en) | 2008-01-16 |
| AU2006207750A1 (en) | 2006-07-27 |
| TNSN07271A1 (en) | 2008-12-31 |
| WO2006076927A2 (en) | 2006-07-27 |
| ZA200706091B (en) | 2008-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2344083C2 (en) | Ferric sulphate based phosphate absorbent | |
| EP0316357A1 (en) | Calcium hypochlorite compositions | |
| EP1851300A2 (en) | General solvent synthesis, production and utility | |
| CA2423977A1 (en) | Sodium percarbonate fluid bed granulated material and method for the production thereof | |
| US4087371A (en) | Method of preventing incrustation on heated surfaces, and composition for the practice of the method | |
| SU806615A1 (en) | Filtering material for waste water purification from nonferrous metal ions, oil products and synthetic surface-active substances | |
| RU2238735C1 (en) | Agent for litholysis of urinary calculus and method for its preparing | |
| SU709662A1 (en) | Invert emulsion drilling mud | |
| JPS5678680A (en) | Treatment for water containing fluoride ion | |
| JPS6340575B2 (en) | ||
| SU1350169A1 (en) | Method of fighting solonetzification soils in water application | |
| US3514269A (en) | Process for manufacture of dimagnesium aluminosilicate for medical uses | |
| SU620257A1 (en) | Land-improving agent for acid sod-podsolic soils | |
| PT94382A (en) | PROCESS FOR THE TREATMENT OF WATER | |
| HU229525B1 (en) | Retarding agents for preparing purified brine | |
| RU2100293C1 (en) | Composition for water softening | |
| JPH0124731B2 (en) | ||
| JPS6139876B2 (en) | ||
| DE420910C (en) | Process for the preparation of double compounds from aliphatic amino acids and inorganic alkali salts | |
| JPH0730473B2 (en) | Strong acid solution for cleaning and purification | |
| US2598004A (en) | Stabilized tetrathiodilactic and tetathiodiglycollic acid pharmaceutical | |
| DE343148C (en) | Process for the production of metal salt compounds of pyridine betaine | |
| JPS6354647B2 (en) | ||
| JPS646833B2 (en) | ||
| IE58134B1 (en) | High-density antacid powders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20070824 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL BA HR MK YU |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1104057 Country of ref document: HK |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20100316 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C11D 7/26 20060101ALI20100310BHEP Ipc: C11D 7/10 20060101ALI20100310BHEP Ipc: C11D 7/00 20060101AFI20060801BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20100803 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1104057 Country of ref document: HK |